---
id: aga-h-pylori-2024
title: "AGA 2024 Clinical Practice Update: Management of Helicobacter pylori Infection"
short_title: "AGA H. pylori 2024"

organization: American Gastroenterological Association
collaborators: null
country: US
url: https://www.gastro.org/guidelines
doi: null
pmid: null
open_access: true

specialty: gastroenterology
guideline_type: clinical-practice
evidence_system: AGA
conditions:
  - Helicobacter pylori
  - H. pylori gastritis
  - peptic ulcer disease
tags:
  - triple therapy
  - quadruple therapy
  - bismuth
  - clarithromycin
  - eradication

publication_date: 2024-03-01
previous_version_date: 2021-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 AGA clinical practice update on the diagnosis and treatment of Helicobacter pylori infection.

## Key Recommendations

### When to Test
- Peptic ulcer disease (active or history of).
- Dyspepsia (test-and-treat strategy).
- MALT lymphoma.
- Prior to long-term NSAID or low-dose aspirin use (consider).
- Unexplained iron deficiency anemia.
- Immune thrombocytopenia (ITP).
- After endoscopic resection of early gastric cancer.

### Diagnostic Testing
- **Non-Invasive**: Urea breath test (UBT), stool antigen test. Hold PPIs for 2 weeks, antibiotics/bismuth for 4 weeks before testing.
- **Invasive (Endoscopy)**: Histology, rapid urease test, culture.
- UBT and stool antigen have high sensitivity/specificity.

### First-Line Treatment (Areas with <15% Clarithromycin Resistance or Unknown)
- **Bismuth Quadruple Therapy (Preferred)**: PPI BID + bismuth subsalicylate QID + metronidazole 500 mg TID + tetracycline 500 mg QID x 14 days.
- **Clarithromycin Triple Therapy**: PPI BID + clarithromycin 500 mg BID + amoxicillin 1 g BID x 14 days. (Avoid if prior macrolide exposure or local resistance ≥15%.)

### First-Line (High Clarithromycin Resistance Areas)
- Bismuth quadruple therapy (above).
- OR Concomitant therapy: PPI BID + clarithromycin 500 mg BID + amoxicillin 1 g BID + metronidazole 500 mg BID x 14 days.

### Treatment Failure (2nd Line and Beyond)
- Avoid previously used antibiotics.
- Bismuth quadruple therapy if not used initially.
- Levofloxacin-based regimens (PPI + levofloxacin + amoxicillin x 14 days).
- Rifabutin-based regimen for multiply-refractory cases.

### Confirm Eradication
- Test ≥4 weeks after completing therapy (UBT or stool antigen).
- Confirm eradication in all patients treated for H. pylori.
